

## SPECIALTY GUIDELINE MANAGEMENT

### **XENAZINE (tetrabenazine) Tetrabenazine (generic)**

#### **POLICY**

##### **I. INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### **A. FDA-Approved Indications**

Treatment of chorea associated with Huntington's disease

###### **B. Compendial Uses**

1. Chronic tics
2. Tardive dyskinesia
3. Hemiballismus
4. Chorea not associated with Huntington's disease

All other indications are considered experimental/investigational and are not a covered benefit.

##### **II. CRITERIA FOR APPROVAL**

###### **A. Chorea**

Authorization of 12 months may be granted for treatment of chorea.

###### **B. Chronic tics**

Authorization of 12 months may be granted for treatment of chronic tics.

###### **C. Tardive dyskinesia**

Authorization of 12 months may be granted for the treatment of tardive dyskinesia.

###### **D. Hemiballismus**

Authorization of 12 months may be granted for the treatment of hemiballismus.

##### **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### **IV. REFERENCES**

1. Xenazine [package insert]. Deerfield, IL: Lundbeck Inc.; June 2015.
2. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado. Available at <http://www.micromedexsolutions.com>. Accessed September 9, 2016.
3. AHFS Drug Information. <http://online.lexi.com/lco>. Accessed September 9, 2016.
4. Clinical Consult. CVS Caremark Clinical Program Review: Focus on Parkinson's Disease and Movement Disorders Programs. October 14, 2009.

5. Clinical Consult. CVS Caremark Clinical Program Review: Focus on Xenazine Programs. November 10, 2008.
6. Clinical Consult. CVS Caremark Clinical Program Review: Focus on Parkinson's Disease and Movement Disorders Programs. October 18, 2010.
7. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. *Am J Geriatr Pharmacother*. 2010;8:331-373.
8. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2012;79(6):597-603.
9. Clinical Consult. CVS Caremark Clinical Program Review: Focus on Parkinson's Disease and Movement Disorders Programs. October 13, 2016.
10. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. *Movement Disorders*. 2007; 22(2): 193-7.